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Abstract
Purpose To investigate the eYcacy and safety of dienogest
as a long-term treatment in endometriosis, with follow-up
after treatment discontinuation. The study included women
with endometriosis, who had previously completed a 12-week,
placebo-controlled study of dienogest, who participated in
an open-label extension study for up to 53 weeks. Thereafter,
a patient subgroup was evaluated in a 24-week follow-up
after treatment discontinuation.
Methods A multicenter study performed in Germany,
Italy and Ukraine. Women with endometriosis were
enrolled at completion of the placebo-controlled study
(n = 168). All women received dienogest (2 mg once daily,
orally) and changes in pelvic pain (on a visual analog
scale), bleeding pattern, adverse events and laboratory
parameters were evaluated during and after treatment.
Results The completion rate among women who entered
the open-label extension study was 90.5% (n = 152). A sig-
niWcant decrease in pelvic pain was shown during contin-
ued dienogest treatment (P < 0.001). The mean frequency
and intensity of bleeding progressively decreased. Adverse
events, rated generally mild or moderate, led to withdrawal
in four patients (2.4%). No clinically relevant changes in
laboratory parameters were observed. During treatment-
free follow-up (n = 34), the reduction in pelvic pain
persisted, while bleeding frequency and intensity returned
to normal patterns.
Conclusions Long-term dienogest showed a favorable
eYcacy and safety proWle, with progressive decreases in
pain and bleeding irregularities during continued treatment;
the decrease of pelvic pain persisted for at least 24 weeks
after treatment cessation.
Keywords Dienogest · Endometriosis · Progestins · 
Pain · Safety
Introduction
Endometriosis is a chronic, benign disease causing symp-
toms of pelvic pain, dysmenorrhea and dyspareunia that
often relapse after surgical therapy [1]. The aim of most
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medical therapies is to decrease the symptoms in order to
improve quality of life, but many are associated with
adverse eVects that restrict their long-term use.
Gonadotropin-releasing hormone (GnRH) agonists are
associated with symptoms of estrogen deprivation (e.g., hot
Xushes, vaginal dryness, headache and decreased libido) and
with bone demineralization that restricts use to 6 months in
the absence of add-back therapy [2, 3]. In addition, the dura-
tion of symptom relief following treatment cessation is typi-
cally short, decreasing the cost-eVectiveness of GnRH
agonists as compared to other approaches [2].
Combined oral contraceptives, while widely used to
manage symptoms of endometriosis, are not approved for
this indication in most countries and their use is largely
unsupported by solid clinical trial evidence [4]. One study
has demonstrated that the use of a low-dose oral contraceptive
pill is an eVective treatment for dysmenorrhea associated
with endometriosis [5].
The widespread use of danazol in endometriosis is lim-
ited by adverse eVects typical of androgenic steroids, such
as alterations in lipid proWle, weight gain, edema, acne,
hirsutism and oily skin [6], although, in deeply inWltrating
endometriosis, vaginal use may increase compliance [7].
Progestins are a recommended treatment for the pain
associated with endometriosis, but a number of agents in
this class are associated with androgenic eVects and weight
gain at the doses that are required for eYcacy [8]. Long-
term use of depot medroxyprogesterone acetate prepara-
tions impacts adversely on bone mineral density (BMD)
[9]. Norethisterone acetate is a potent progestin derivative
of 19-norethisterone and is valid for use in patients with
endometriosis [8]; however, its main side eVects include
breast tenderness, weight gain, acne and hirsutism, in
addition to breakthrough bleeding. Levonorgestrel (LNG)
has also been used for treating women with symptomatic
minimal-to-moderate endometriosis [10], leading to
improvements in the severity and frequency of pain and men-
strual symptoms. The LNG-intrauterine device (LNG-IUD)
is an eVective treatment for rectovaginal endometriosis in
women who have previously undergone conservative surgery
without excision of deep lesions [11]. However, the LNG-IUD
is not approved for the treatment of endometriosis.
There remains, therefore, a need for an eVective, safe
and well-tolerated medical therapy that can be used in the
long-term management of endometriosis. Dienogest is a
selective progestin that combines the pharmacologic prop-
erties of 19-norprogestins and progesterone derivatives,
oVering a potent progestogenic eVect at the endometrium.
Clinical trials of 12–24 weeks’ duration have shown that
dienogest (at a dose of 2 mg/day) provides eVective pain
relief equivalent to GnRH agonists, a reduction of endome-
triotic lesions and a favorable safety and tolerability proWle
in endometriosis [12–14].
A recent Japanese study investigated the eYcacy of
52 weeks of dienogest administration for the treatment of
endometriosis [15] and reported a marked or moderate
improvement in symptoms in 90.6% of patients, with low
rates of adverse event-related discontinuations and little
impact on BMD.
In a recent, double-blind, placebo-controlled European
study of 198 women with endometriosis, dienogest for
12 weeks was signiWcantly more eVective than placebo in
reducing endometriosis-associated pelvic pain (EAPP),
with low rates of treatment-related adverse events [16].
With the aim to investigate the long-term safety and
eYcacy of continuous dienogest treatment of endometriosis
in this European network, a 1-year, open-label extension
study to this placebo-controlled study was performed. In
addition, at completion of the extension study, a subgroup
of women was followed for 24 weeks without dienogest
treatment.
Materials and methods
Women with laparoscopically conWrmed endometriosis
who participated in a 12-week, multicenter, randomized,
double-blind, placebo-controlled study of dienogest treat-
ment at 2 mg once daily [16] were oVered and accepted par-
ticipation in an open-label, single-arm extension study of
dienogest treatment (n = 168). The extension study was
conducted at 28 centers in Germany (n =1 7 ) ,  I t a l y  ( n =5 )
and Ukraine (n = 6) between July 2004 and November
2007. The duration of treatment was initially planned to be
36 weeks, but was extended to 52 weeks during the course
of the study. Twenty-six patients completed the study
before this prolongation was introduced to the protocol. For
the Wnal visit, a deviation of +1 week was allowed, result-
ing in a maximum treatment duration of 12 weeks (in the
placebo-controlled study) plus 53 weeks in the current
study (total 65 weeks). An additional 24 weeks, treatment-
free follow-up was conducted in a patient subgroup
(n = 34) at six study centers on completion of the extension
study. Therefore, an overall total of 90 weeks of study was
conducted.
The study protocol was approved by local independent
ethics committees and all participants provided written,
informed consent before study enrolment. The study was
conducted in accordance with the amended version of the
Declaration of Helsinki and complied with Good Clinical
Practice guidelines.
Inclusion and exclusion criteria for participation in the pla-
cebo-controlled study are described in detail elsewhere [16]. In
brief, the inclusion criteria for women aged 18–45 years
included histologically proven endometriosis (stages 1–4)
at laparoscopy ·12 months before study entry [17] and anArch Gynecol Obstet (2012) 285:167–173 169
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EAPP score of at least 30 mm on a 100-mm visual analog
scale (VAS) at screening and baseline visits [16]. All
women, who completed their allocated treatment with
either dienogest or placebo in the placebo-controlled study,
without major protocol violations, were eligible for inclu-
sion in the extension study. All patients at speciWc study
centers who successfully completed the extension study
were subsequently eligible for inclusion in the follow-up
study.
Dienogest was administered at a dose of 2 mg once
daily, orally, for up to 53 weeks to all women during the
extension study. The Wrst dienogest tablet during the exten-
sion study was taken on the day after medication ended in
the placebo-controlled study. Women completed a daily
diary card throughout the extension study to monitor treat-
ment compliance. Investigators recorded the use of any
concomitant medications.
The main study variables were (1) EAPP, which was
assessed by VAS score every 4 weeks to summarize the
previous 4-week period (where 0 mm represents absence of
pain and 100 mm indicates unbearable pain); (2) uterine
bleeding pattern, which was assessed over 90-day periods
according to the method of Gerlinger et al. [18]. Women
documented the presence and intensity of bleeding on daily
diary cards, from which the frequency and duration of
bleeding events were calculated.
Patient visits were planned at baseline and at weeks 2,
13, 25, 36 and 52 of the extension study, as well as at weeks
12 and 24 during the treatment-free follow-up.
Adverse events were documented at all study visits and
coded according to the Medical Dictionary for Regulatory
Activities Primary System Organ Class. Adverse events were
rated treatment-related at the discretion of the investigator.
Laboratory assessments included hematology, blood chemis-
try, liver enzyme, lipid and estradiol concentration mea-
surements (Laboratorium für Klinische Forschung, Kiel,
Germany) and dipstick urinalysis (“Combur-9”; Roche,
Germany). Gynecologic examination (including cervical
cytological smears), breast examination, vital sign assess-
ments (blood pressure and heart rate) and body weight mea-
surements were performed at predeWned study visits.
Abnormal  Wndings at gynecologic and breast examination
were reported as adverse events. Urine pregnancy testing was
performed at home every 4 weeks and at study visits.
Quality of life assessments by the Short Form 36 Health
Survey Questionnaire (SF-36®) were performed at the base-
line and the end of the follow-up study to measure changes
in mental and physical components.
Statistical analyses
Analyses are based on the full analysis set (FAS), which
included all women who took at least one dose of study
medication and provided at least one observation after dos-
ing. Subgroup analyses are reported for women treated with
dienogest or placebo during the previous placebo-
controlled study (“prior-dienogest” and “prior-placebo”
groups, respectively).
The eYcacy and safety analyses in the extension and
follow-up studies are presented primarily as descriptive sta-
tistics. The null hypothesis of whether the change in EAPP
from randomization in the placebo-controlled study to the
end of the extension study was equal to 0 was exploratively
tested using the one-sample t test.
The sample size of the extension study was determined
by the number of women who were eligible and willing to
participate at completion of the placebo-controlled study.
According to the guidelines from the International Confer-
ence on Harmonization, the extent of population exposure
to assess clinical safety requires at least 100 patients stud-
ied over 1 year. Assuming a dropout rate of 25%, the exten-
sion study, therefore, required inclusion of a minimum of
133 women.
Results
Among women who completed the placebo-controlled
study (n = 188), 168 entered the extension study and were
included in the FAS (Fig. 1). A total of 152 women (90.5%)
completed the planned duration of the extension study
(n = 17, 36 weeks; n = 135, 52 weeks). No predominant
reason for withdrawal was identiWed among women who
discontinued. Treatment compliance, measured by daily
diary cards during the extension study, was 98.3%. A sub-
group of 34 women at six study centers began the
24 weeks, treatment-free follow-up, with completion by 31
(91.2%) (Fig. 1).
Pelvic pain
The mean VAS score at baseline of the extension study was
34.08 mm (standard deviation [SD] §21.60 mm) in the total
population, resulting from mean scores of 27.89 (§20.24) mm
in the dienogest-treated and 40.73 (§21.14) mm in the pla-
cebo-treated subgroup. The mean VAS score progressively
and signiWcantly decreased to 11.52 (§11.26) mm at the end
of the extension study in the total population (9.72 § 7.44 mm
in the prior-dienogest group and 13.49 § 14.14 mm in the
prior-placebo group) (Fig. 2). The mean VAS score was statis-
tically signiWcantly reduced by 43.2 (§21.7) mm over the total
treatment period of 65 weeks (i.e., the placebo-controlled plus
extension study; P < 0.001).
During the treatment-free follow-up, the mean VAS score
increased slightly from the end of the extension study to 16.29
(§14.08) mm at week 12 and 14.56 (§9.55) mm at week 24.170 Arch Gynecol Obstet (2012) 285:167–173
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Uterine bleeding pattern
Continued dienogest treatment during the extension study
was associated with a progressive reduction in the number
of bleeding/spotting days, number of bleeding/spotting
episodes and duration of bleeding/spotting episodes
between 90-day reference periods.
Subgroup analysis during the extension study showed
that both the prior-dienogest and the prior-placebo sub-
groups of the placebo-controlled study experienced
decreases in the number of bleeding/spotting days, number
of spotting episodes and duration of bleeding/spotting epi-
sodes. These decreases were greater in the prior-placebo
than in the prior-dienogest subgroup.
When comparing the frequency of maximal intensity of
bleeding between 90-day reference periods 1 and 4, a sub-
stantial increase in the “no bleeding” category, i.e., women
who never bled during the entire reference period (from 5.5
to 23.5% of women) and a decrease in the “heavy bleeding”
category (from 9.8 to 2.2%) was shown (Fig. 3). During
treatment-free follow-up, bleeding returned to normal
cyclic patterns and intensity within 4–6 weeks. No patients
reported amenorrhea or spotting during the Wnal 90-day ref-
erence period of treatment-free follow-up.
Safety variables
Laboratory parameters (Table 1), vital signs and body
weight remained stable or underwent minimal changes dur-
ing the extension study. In patients whose body weight was
assessed at both baseline and after 52 weeks of treatment
(n = 124), a mean change of 0.58 (§2.09) kg was recorded.
Laboratory parameters continued to show no or minimal
changes during treatment-free follow-up, while vital sign
and body weight assessments provided stable results.
Fig. 1 Patient disposition dur-
ing the extension study and the 
treatment-free follow-up period
Fig. 2 Mean (§SEM) VAS scores for EAPP during the extension
study (FAS) in the total, prior-dienogest and prior-placebo groups.
Mean VAS score was statistically signiWcantly reduced by 43.2
(§21.7) mm over the total treatment period of 65 weeks (i.e., placebo-
controlled plus extension study; P <0 . 0 0 1 ) .  EAPP endometriosis-
associated pain, FAS full analysis set, SEM standard error of the mean,
VAS visual analog scaleArch Gynecol Obstet (2012) 285:167–173 171
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Adverse events considered potentially drug related by
the investigators developed in 27/168 women (16.1%)
during the extension study, including breast discomfort
(n = 7; 4.2%), nausea (n = 5; 3.0%) and irritability (n =4 ;
2.4%). The maximal intensity of treatment-related adverse
events was rated mild or moderate in the majority (92.5%)
of cases. Three women (1.8%) experienced one serious
adverse event each of cholelithiasis, chronic sinusitis and
depression; of these, only the case of depression, which
developed after approximately 4 months of study drug
treatment, was considered to be possibly treatment related.
Four women (2.4%) experienced four adverse events
(i.e., weight increase, migraine, depression and breast pain)
that led to premature study discontinuation (Fig. 1). Two
women (1.2%) discontinued the study due to bleeding-
related events (amenorrhea and polymenorrhea), which
were not recorded as adverse events. Abnormal cervical
smear Wndings were recorded in two women, which were
considered unlikely to be treatment related.
During treatment-free follow-up, 7/34 women (20.6%)
developed de novo adverse events, including headache in
two women (5.9%). One woman developed an ovarian cyst
at the end of the follow-up period that was considered to be
unrelated to previous study drug intake. Another woman
had a successful, planned pregnancy, with conception esti-
mated at approximately 6 months after ceasing treatment.
Quality of life assessment by the SF-36® indicated minimal
change in mental or physical sum scores during the follow-
up period.
Fig. 3 Frequencies of maximal intensity of bleeding in 90-day refer-
ence periods 1 and 4 during dienogest treatment in the extension study
(FAS) FAS full analysis set
Table 1 Selected laboratory parameters during dienogest treatment in the extension study
Values are number of women or mean § SD
HbA1C hemoglobin A1C, HDL high-density lipoprotein, LDL low-density lipoprotein
a Includes patients with a predeWned treatment duration of 36 or 52 weeks, respectively
Parameter Baseline of extension 
study
Absolute change from 
baseline to end 
of treatmenta
Normal range
n Mean § SD n Mean § SD
Hematology
Erythrocytes (1012/L) 167 4.46 § 0.34 155 –0.01 § 0.30 3.6–5.0
Leukocytes (109/L) 166 5.94 § 1.82 154 0.21 § 2.15 4.0–10.0
Platelets (g/L) 167 248.4 § 66.40 155 –1.3 § 60.60 150–450
HbA1c (%) 168 5.16 § 0.31 157 –0.13 § 0.29 4.3–6.1
Serum lipid concentrations
Total cholesterol (mmol/L) 168 4.86 § 0.97 161 –0.05 § 0.94 4.14–6.73
HDL cholesterol (mmol/L) 168 1.53 § 0.33 161 –0.04 § 0.36 1.09–2.28
LDL cholesterol (mmol/L) 168 2.91 § 0.75 161 0.10 § 0.71 1.97–5.65
Triglycerides (mmol/L) 168 1.05 § 0.61 161 0.03 § 0.57 0.80–1.94
Liver enzymes
Alkaline phosphatase (U/L) 168 54.2 § 17.61 161 3.6 § 17.36 35–104
Gamma glutamyl transferase (U/L) 168 18.1 § 16.40 161 2.3 § 23.66 5–39
Alanine aminotransferase (U/L) 168 15.2 § 11.35 161 1.6 § 13.61 0–31
Cholinesterase (U/L) 168 7,463.4 § 1,421.20 161 –116.9 § 1,473.26 3,650–11,250
Hormones
Estradiol (nmol/L) 163 0.26 § 0.32 151 0.02 § 0.44 0.03–1.03172 Arch Gynecol Obstet (2012) 285:167–173
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Discussion
The present study shows that dienogest treatment for up to
65 weeks is associated with reduced pelvic pain in women
with endometriosis, and that this eVect persists for at least
24 weeks after the end of treatment. Previous studies of
dienogest treatment for periods of 12–24 weeks reported
superior eYcacy relative to placebo [16] and equivalent
eYcacy compared with leuprolide acetate and buserelin
acetate [14, 19] in relieving the symptoms of endometri-
osis. The present Wndings suggest that dienogest represents
an eVective treatment over the long term. The observation
that pain relief is also largely maintained during the
24 weeks after treatment cessation may indicate that
dienogest—at least for a certain period—sustains a beneW-
cial eVect that exceeds the period of symptomatic treat-
ment. One plausible explanation for this eVect is the
reduction in endometriotic lesions observed during dieno-
gest treatment [13], although additional explanations for the
sustained reduction in pain are possible. Dienogest and
other progestins have a number of putative mechanisms of
action in endometriosis, including reduced growth, prolifer-
ation and neoangiogenesis of lesions [20, 21] as well as an
antiinXammatory eVect [22].
Assessment of uterine bleeding by a number of analyses
showed that dienogest is associated with a desynchronized
uterine bleeding in the short term, but with a progressive
reduction in the frequency and intensity of bleeding during
continued treatment. Irregular bleeding has also been
reported in short-term studies of dienogest treatment
[13, 16, 19]. The bleeding pattern associated with dienogest
appeared to be generally acceptable, as only 2 of 168
women in the extension study discontinued treatment due
to changes in their bleeding pattern. The incidence of
menorrhagia was lower in this study than in the Japanese
long-term study, which reported a 71.9% incidence of
menorrhagia; in that study, 18 of 135 patients (13.3%)
discontinued treatment for various reasons [15].
Irregular uterine bleeding is a known common adverse
eVect of all long-term progestin treatments [8]. Informing
women of the bleeding proWle of dienogest before they ini-
tiate treatment will likely enhance their long-term adher-
ence to therapy in light of the accompanying improvement
in painful symptoms.
The safety variables included in the extension study also
indicated an acceptable proWle for dienogest. The lack of
changes in laboratory parameters supports previous trials
that investigated the metabolic eVects of dienogest [13, 14,
16, 23]. In addition, there were minimal changes in mean
body weight, consistent with the previous dienogest
experience [13, 14, 16].
This study contributes to the evidence base on medica-
tions investigated for the long-term treatment of endometri-
osis. The strengths of the current study include the
assessment of clinically relevant outcomes, the long-term
(1 year) treatment duration, and a treatment-free follow-up,
which are pertinent for the management of patients with
endometriosis. The data from the follow-up period may be
especially relevant for patients who wish to become pregnant
after a course of medical therapy. Potential weaknesses of the
study are its open-label design and the recruitment of patients
who had participated in an earlier placebo-controlled study,
which included a proportion who responded favorably to
prior dienogest therapy. The low and comparable discontinu-
ation rates in both subgroups, during and at the end of the
placebo-controlled study indicate that this theoretical concern
did not introduce a major bias.
In summary, this large-scale, long-term study showed
that dienogest treatment induces a sustained reduction in
EAPP associated with a favorable safety and tolerability
proWle. The observation of prolonged pain relief even after
the return of normal menses suggests a sustained eVect on
endometrial lesions. Bleeding irregularities demonstrated a
tendency toward reduced frequency and intensity during
continued treatment. Therefore, dienogest may represent
an eVective long-term treatment option for women with
endometriosis.
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